LSE:C4XD (C4x Discovery Plc)

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. Its software platforms consists of Taxonomy3, which utilizes a mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases; and Conformetrix, which determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.